Abstract 728P
Background
Cervical function damage from fertility-sparing surgery reduces pregnancy success rate. Recently, immunotherapy has made significant advances in treating cervical cancer (CC). Herein, we conducted this study to evaluate the efficacy and safety of chemo + tislelizumab (TIS, a PD-L1 inhibitor) in young pts with CC who required fertility preservation.
Methods
In this trial, FIGO2018 stage IB1-IB3 or IIIC1r (localized cervical lesions) CC and having fertility needs were enrolled. Pts received 4 cycles chemo (175 mg/m2 paclitaxel + 70 mg/m2 cisplatin/AUC 5-6 carboplatin, Q3W) + TIS (200 mg, Q3W), followed by surgery-diagnostic cervical conization and sentinel lymph node (SLN) biopsy (IIIC1r stage with pelvic lymph node [PLN] systematic dissection)-upon achieving radiographic complete response (CR). After surgery, pts with pathological complete response (pCR) in all samples will undergo 2-cycle chemo + TIS, followed by TIS maintenance therapy (MT) for 1 year. If the first conization did not achieve pCR for localized cervical lesion only, a second conization was performed after 2-cycle chemo + TIS, followed by 1 year of TIS MT upon achieving pCR. Primary endpoint was pCR (SLN/PLNs + cervical conization) after surgery.
Results
Between Mar. 2022 and Apr. 2024, 8 pts (mean age 31 years) were enrolled, with 2 having stage IIIC1r disease. All 8 pts received chemo + TIS; of these, 6 pts completed 4 cycles, CR rate was 83.3%(5/6), and patients with CR received surgery. The pCR was 100% (5/5) in pts who underwent surgery, with 1 reaching a pCR after the second conization. Amenorrhea occurred in 3 of 5 pts, with 2 recovering normal menstruation post-chemo, and 1 had not returned after 3 weeks post-last chemo+TIS. During 4 cycles of chemo+TIS therapy (n=7), common TEAEs included rash (62.5%), neutropenia (62.5%), and leukopenia (62.5%), alanine aminotransferase increased (50.0%). At data cutoff (median follow-up, 9 months, range 2-25), 1 pt developed progression during MT, and 1 pt got pregnant 3 months post-MT.
Conclusions
Chemo + TIS could mediate tumor regression and eliminate micro-metastases with a tolerable safety profile, potentially preserving fertility in many pts previously considered ineligible.
Clinical trial identification
ChiCTR2300067495.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
682TiP - A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Presenter: Shigehiro Koganemaru
Session: Poster session 01
683TiP - A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study
Presenter: Hiromichi Nakajima
Session: Poster session 01
684TiP - A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
Presenter: Bhumsuk Keam
Session: Poster session 01
685TiP - A phase I, multicenter trial (“KinLET”) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age
Presenter: Maria Cristina Mata Fernandez
Session: Poster session 01
687TiP - A phase I, first in human study of TORL-4-500 in patients with advanced cancer
Presenter: Jonathan Goldman
Session: Poster session 01
688TiP - Phase I dose escalation trial to evaluate safety and preliminary efficacy of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors
Presenter: Xihui Hu
Session: Poster session 01
689TiP - A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors
Presenter: Vaia Florou
Session: Poster session 01
690TiP - HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
Presenter: Thomas Powles
Session: Poster session 01
691TiP - PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Presenter: Alison Schram
Session: Poster session 01